Development and validation of a new screening tool for hypoactive sexual desire disorder: The Brief Profile of Female Sexual Function<sup>©</sup>(B-PFSF<sup>©</sup>)

Rust, John; Derogatis, Leonard R.; Rodenberg, Cynthia; Koochaki, Patricia; Schmitt, Sonja; Golombok, Susan

doi:10.1080/09513590701592306

Cited by 52 publications

(29 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of general sexual function questionnaires have been developed and utilized in the evaluation of women with PFD, including the Female Sexual Function Index (FSFI) [5], the Profile of Female Sexual Function (PFSF) [6], and the McCoy Female Sexuality Questionnaire (MFSQ) [7]. While these measures are validated, they were not developed to focus on PFD and its impact on sexual health, and because they are not condition-specific for PFD, they may not be sensitive enough to detect differences in sexual function due to PFD.…”

Section: Introductionmentioning

confidence: 99%

A new measure of sexual function in women with pelvic floor disorders (PFD): the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR)

et al. 2013

View full text Add to dashboard Cite

Introduction and hypothesis The objective of this study was to create a valid, reliable, and responsive sexual function measure in women with pelvic floor disorders (PFDs) for both sexually active (SA) and inactive (NSA) women. Methods Expert review identified concept gaps and generated items evaluated with cognitive interviews. Women underwent Pelvic Organ Prolapse Quantification (POPQ) exams and completed the Incontinence Severity Index (ISI), a prolapse question from the Epidemiology of Prolapse and Incontinence Questionnaire (ISI scores), the Pelvic Floor Distress Inventory-20 (PFDI-20), and the Female Sexual Function Index (FSFI). Principle components and orthogonal varimax rotation and principle factor analysis with oblique rotation identified item grouping. Cronbach's alpha measured internal consistency. Factor correlations evaluated criterion validation. Change scores compared to change scores in other measures evaluated responsiveness among women who underwent surgery. Results A total of 589 women gave baseline data, 200 returned surveys after treatment, and 147 provided test-retest A related editorial can be found at

show abstract

Section: Introductionmentioning

confidence: 99%

A new measure of sexual function in women with pelvic floor disorders (PFD): the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR)

et al. 2013

View full text Add to dashboard Cite

show abstract

“…227 -Level of nicotine dependence measured with the 228 Fagerstrom Test for Nicotine Dependence (FTND) to 229 evaluate smoking [36][37][38][39]. [41][42][43]. 236 -Compliance with nutritional habits measured with the 237 Lifestyle Associated Questionnaire [44,45].…”

mentioning

confidence: 99%

A specific nursing educational program in patients with Cushing’s syndrome

et al. 2015

View full text Add to dashboard Cite

10 Abstract Cushing's syndrome (CS) is a rare endocrine 11 disease, due to cortisol hypersecretion. CS patients have 12 comorbidities, often still present after biochemical cure. 13 Specific nursing healthcare programs to address this dis-14 ease and achieve improved health related quality of life 15 (HRQoL) are lacking. Thus, an educational nursing inter-16 vention, through the development and promotion of 17 specific educational tools, appears to be justified. The 18 objective of this study is to assess the effectiveness of an 19 educational nursing program in CS patients on HRQoL, 20 clinical parameters, level of pain and physical activity, 21 patterns of rest, and use of health resources. A prospective, 22 randomized study was conducted in two reference hospitals 23 for CS. Sixty-one patients (mean age 47 ± 12.7 years, 24 83.6 % females) were enrolled and divided into 2 groups: 25 an ''intervention'' group where educational sessions were 26 performed over 9 months and a ''control'' group, without 27 these sessions. Specific questionnaires were used at the 28 beginning and end of the study. After educational sessions, 29 the intervention group had a better score in the Cush-30 ingQoL questionnaire (p \ 0.01), reduced level of pain 31 (p \ 0.05), improved physical activity (p \ 0.01) and 32 healthy lifestyle (p \ 0.001) compared to the control 33 group. A correlation between the CushingQoL score and 34 reduced pain (r = 0.46, p \ 0.05), improved physical 35 activity (r = 0.89, p \ 0.01), and sleep (r = 0.53, 36 p = 0.01) was observed. This educational nursing program 37 improved physical activity, healthy lifestyle, better sleep 38 patterns, and reduced pain in CS patients, influencing 39 HRQoL and reducing consumption of health resources. 40 Moreover, the brief nature of the program suggests it as a 41 good candidate to be used in CS patients. Patients with cushing's syndrome (CS) suffer from multi-47 ple comorbidities, mainly cardiovascular (hypertension, 48 atherosclerosis, changes in heart functionality), and meta-49 bolic (dyslipidemia, central obesity, diabetes), as well as 50 thrombotic disorders, bone disorders, cognitive and neu-51 ropsychological impairment, and impaired sexual function 52 due to glucocorticoid (GC) excess [1][2][3][4][5][6].53 The assumption that resolution of hypercortisolism 54 normalized comorbidities is currently questioned, since R E V I S E D P R O O F55 there is evidence that cured CS patients still have increased 56 morbidity and mortality despite endocrine control [7][8][9]. 57 Most patients with CS develop metabolic syndrome, which 58 may persist after remission of hypercortisolism, con-59 tributing to increased cardiovascular risk and deserve to be 60 treated according to common standard practice [7]. 61 Awareness of this persistent increase in cardiovascular risk 62 in CS patients after endocrine cure leads to strict control of 63 improvable factors, including blood pressure, dyslipemia, 64 hyperglycemia, smoking, obesity, and prothrombotic state 65 [10]. 66 There is am...

show abstract

“…All transsexual women had their SRS in the years 2006 and 2007. A B-PFSF score %20 reportedly indicates clinically relevant HSDD (24). Some transsexual women were treated with a transdermal patch administering testosterone at 300 mg/day (Intrinsa TTS, Procter & Gamble Pharmaceuticals; Darmstadt, Germany) or others with oral dydrogesterone 10 mg/day (Duphaston 10 mg; Solvay Arzneimittel, Hanover, Germany), depending on their own preference.…”

Section: Patients and Sex Hormone Treatmentmentioning

confidence: 99%

“…The item scores were transformed (neverZ0 points; alwaysZ5 points) so that lower scores were indicative of poorer sexual function and higher distress. A total score for the B-PFSF is obtained by summing the scores for each item, resulting in a total score ranging from 0 to 35, while a cut-off of 20 was found to be clinically relevant in categorizing women as possibly having HSDD or not (24).…”

Section: Brief Profile Of Female Sexual Functionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of transdermal testosterone or oral dydrogesterone on hypoactive sexual desire disorder in transsexual women: results of a pilot study

Kronawitter

Gooren

Zollver³

et al. 2009

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: It has been reported that hypoactive sexual desire disorder (HSDD) affects one-third of transsexual women (defined as postoperative male-to-female transsexuals) receiving estrogen replacement whose bioavailable androgen levels are lower than in ovulating women and comparable with those in surgically postmenopausal women. The aim of this study was to evaluate the efficacy of transdermal testosterone treatment and of oral dydrogesterone in transsexual women with HSDD receiving estrogens. Methods: Seven transsexual women with HSDD were treated with a testosterone patch and nine transsexual women with HSDD were treated with oral dydrogesterone over 24 weeks. The primary end point was the change in the brief profile of female sexual function (B-PFSF) score. Secondary end points were changes in hormonal parameters and side effect assessments. Results: A significant increase in total testosterone and free testosterone levels was observed in the group receiving transdermal testosterone. At 24 weeks, there was a significant improvement in the B-PFSF score showing an improvement in sexual desire among transsexual women treated with the testosterone patch, whereas no change in the B-PFSF score was observed in transsexual women treated with oral dydrogesterone. No side effects were reported. Conclusions: In this pilot study, sexual desire in transsexual women improved significantly after treatment with the testosterone patch, without noticeable side effects.

show abstract

Development and validation of a new screening tool for hypoactive sexual desire disorder: The Brief Profile of Female Sexual Function^©(B-PFSF^©)

Abstract: The Brief Profile of Female Sexual Function (B-PFSF) is psychometrically valid and appropriate for use as a self-administered screening tool.

Cited by 52 publications

References 25 publications

A new measure of sexual function in women with pelvic floor disorders (PFD): the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR)

A new measure of sexual function in women with pelvic floor disorders (PFD): the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR)

A specific nursing educational program in patients with Cushing’s syndrome

Effects of transdermal testosterone or oral dydrogesterone on hypoactive sexual desire disorder in transsexual women: results of a pilot study

Contact Info

Product

Resources

About

Development and validation of a new screening tool for hypoactive sexual desire disorder: The Brief Profile of Female Sexual Function©(B-PFSF©)

Abstract: The Brief Profile of Female Sexual Function (B-PFSF) is psychometrically valid and appropriate for use as a self-administered screening tool.

Cited by 52 publications

References 25 publications

A new measure of sexual function in women with pelvic floor disorders (PFD): the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR)

A new measure of sexual function in women with pelvic floor disorders (PFD): the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR)

A specific nursing educational program in patients with Cushing’s syndrome

Effects of transdermal testosterone or oral dydrogesterone on hypoactive sexual desire disorder in transsexual women: results of a pilot study

Contact Info

Product

Resources

About

Development and validation of a new screening tool for hypoactive sexual desire disorder: The Brief Profile of Female Sexual Function^©(B-PFSF^©)